The Transparency Committee's two grades do different jobs. SMR (actual benefit) sets whether, and at what co-pay rate, the state reimburses. ASMR (improvement over existing care) sets the pricing conversation with CEPS. Confusing the two is the classic outsider error.
The odds, from 521 novel EMA authorisations 2011–2020
Half of the positive decisions never show in community dispensing: hospital-administered drugs are invisible in the French data, not absent from France. Posterior means with 90% credible intervals from our Bayesian pathway model; segment-level odds by technology, disease area and first-in-class status are in the subscription.
The pathway, step by step
Regulatory approval: EMA / ANSM
Standard EMA centralised approval for new substances; ANSM handles national procedures and safety. France's distinctive front door is what comes next: for genuinely innovative drugs in unmet need, accès précoce (early access) can fund use before reimbursement is settled, at a company-set price subject to later clawback against the final negotiated price.
Engage: accès précoce application via HAS: revenue earlier, with a rebate liability attachedTransparency Committee: the two grades
The Commission de la Transparence at HAS assesses the dossier and issues both grades. SMR (important / moderate / weak / insufficient) governs reimbursement and the rate (65% / 30% / 15%); “insufficient” means no reimbursement at all. ASMR (I major → V none) measures improvement over existing therapy and is the input to pricing.
Our data: 1,600 SMR ratings of 15,432 ever graded “insufficient”Price negotiation: CEPS
The pricing committee negotiates under a standing framework agreement with industry. The essential rule: ASMR I, III earn a European-consistent price (with a period of price stability); ASMR IV negotiates hard; ASMR V can only be listed if it saves money against the comparator. This is why 81% of ratings being ASMR V matters: most drugs enter France priced below what they replace.
Engage: CEPS, with European price references and a savings story readyReimbursement lists and the hospital route
City (retail) and hospital lists are distinct, with separate procedures; UNCAM fixes the reimbursement rate from the SMR. Hospital-only medicines route through tenders and the liste en sus for high-cost add-ons.
Re-assessment and clawbacks
The Transparency Committee re-evaluates classes and renews inscriptions; volumes, price-volume clauses and the sector-wide safeguard levy shape net revenue. Accès précoce clawbacks settle when the final price lands.
What the record actually shows
Who decides what, and when to engage
| Institution | What it decides | Evidence it weighs | When to engage |
|---|---|---|---|
| ANSM / EMA Regulators | Licence, label, early-access safety | Efficacy, safety, quality | Scientific advice; accès précoce planning |
| HAS Transparency Committee HTA body | SMR (reimburse? at what rate?) and ASMR (how much better?) | Comparative clinical evidence vs existing care; unmet need; public-health impact | Early advice; dossier at launch; hearings |
| CEPS Pricing committee | The negotiated price and price-volume clauses | The ASMR grade, European prices, volumes, savings offers | Immediately after the CT opinion, with the European picture prepared |
| UNCAM Insurance union | The reimbursement rate applied from the SMR | The SMR grade | Not directly; flows from the CT |
| Ministry / DGS Government | Final listing decisions, hospital policy | System affordability | Rarely direct; sets the framework |
The evidence France actually asks for
Comparison against French practice. The CT judges improvement over existing therapy as used in France. Placebo superiority where an active standard exists reads as ASMR V by default.
Clinically meaningful endpoints. The doctrine favours mortality, morbidity and quality of life demonstrated in the French-relevant population; modest effect sizes on surrogates rarely climb above ASMR IV.
The savings story for ASMR V. Since most drugs land there, the pragmatic dossier pre-computes the price at which listing saves money against the comparator; arriving without one hands CEPS the pen.
Population sizing. Price-volume clauses make French epidemiology part of the negotiation; registry-grade numbers beat modelled ones.
Where companies get hurt
Planning a French launch?
We build Transparency-Committee-ready comparative dossiers and CEPS-aware pricing strategy, including the ASMR V savings case most launches end up needing. Fixed fees, senior-built.
Talk to us